Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.
Biohaven (BHVN) announced a multi-target collaboration with Merus (MRUS). This collaboration will co-develop three programs encompassing highly ...
Pharmaceutical company Pfizer Incorporated on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd., has agreed ...
Get Our Latest Report on Biohaven Biohaven Trading Up 0.3 % Shares of BHVN opened at $40.67 on Wednesday. The company has a market capitalization of $4.11 billion, a PE ratio of -4.35 and a beta ...